AstraZeneca Licenses Global Rights To Oncology Compound From China’s Hutchison
This article was originally published in PharmAsia News
AstraZeneca pays $20 million up front to license Hutchison’s Phase I-ready compound in another sign that the U.K. pharma has its eyes set firmly on China.
You may also be interested in...
Olaparib and TC-5214 development setbacks at AstraZeneca lead to $380 million charge in the fourth quarter, with core EPS likely at the bottom of the expected range.
Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds
SHANGHAI - Hutchison MediPharma, one of China's leading biotechs, announced Nov. 8 that Tokyo-based venture capital firm Mitsui had acquired a 12.2 percent stake in the company for $12.5 million, generating speculation among China watchers that it could be a first step toward self-funding and an eventual IPO for Hutchison